BioN­Tech signs im­munother­a­py deal with Medi­gene as post-Covid strat­e­gy takes shape

4 years ago
Deals

Claim­ing his­toric first, As­traZeneca says En­her­tu aces PhI­II for hard-to-reach seg­ment of pa­tients

4 years ago
R&D

Af­ter rais­ing more than $750M in quick Covid cash, Till­man Gern­gross is on his way out of trou­bled Ada­gio

4 years ago
People
Coronavirus

In­side PBM­s' tac­tics to tilt the mar­ket; Is the KRAS race still on? CAR-T safe­ty scares trig­ger halts; and more

4 years ago
Weekly

When the $10K brand name drug is more af­ford­able than its $450 gener­ic: How PBMs con­trol the sys­tem

4 years ago
Pharma

Pub­lic Cit­i­zen ac­cus­es Pfiz­er of build­ing 'patent wal­l' for Covid treat­ment, set­ting up in­equities again

4 years ago
Pharma
Coronavirus

Roche and As­traZeneca set­tle years­long patent bat­tle over Ul­tomiris — re­port

4 years ago
Pharma

As Mod­er­na adds on a host of new com­mer­cial subs, there's room for 3 more vac­cine can­di­dates in the pipeline

4 years ago
R&D

Track­ing men­tal health: Lund­beck part­ner­ship de­buts US map­ping dash­board tool

4 years ago
Pharma
Marketing

J&J back in court over new gener­ic threat from In­tas, just months af­ter fend­ing off Te­va

4 years ago
Pharma

To keep up with de­mand, Sor­ren­to ac­quires ma­jor­i­ty own­er­ship in Covid-19 test man­u­fac­tur­er

4 years ago
Pharma
Manufacturing

One mi­cro­cap biotech is charg­ing head­first in­to treach­er­ous IPO wa­ters, jump­ing to Nas­daq with mod­est raise

4 years ago
Financing

FDA up­dates Mer­ck­'s Covid-19 pill EUA and reaf­firms it should on­ly be used as a last re­sort

4 years ago
FDA+
Coronavirus

Bay­er's next-gen drug Nube­qa aces sur­vival test in metasta­t­ic prostate can­cer, putting it in com­pe­ti­tion with gi­ants

4 years ago
R&D

FDA starts probe in­to a clin­i­cal tri­al death as next-gen CAR-T re­searchers stop en­roll­ment

4 years ago
Cell/Gene Tx
FDA+

Bio­Marin gene ther­a­py could be on hold 'for sev­er­al quar­ter­s' af­ter FDA man­dates new pre­clin­i­cal tests

4 years ago
R&D
Cell/Gene Tx

In sur­prise flop, Re­gen­eron, Sanofi re­port Dupix­ent PhI­II fail­ure, trig­ger­ing pre­ma­ture tri­al stop

4 years ago
R&D

Af­ter sell­ing off Tib­so­vo and en­tire can­cer pipeline, Agios nets first ap­proval for new 'an­chor pro­duc­t'

4 years ago
FDA+

Am­gen, Ipsen vet moves up the lad­der with Co­herus' an­ti-PD-1 await­ing PDU­FA; It takes a vil­lage to re­place Frank ...

4 years ago
Peer Review

Flash­ing red on RSV ma­ter­nal vac­cine, GSK paus­es PhI­II tri­al fol­low­ing ‘ob­ser­va­tion’ from safe­ty check

4 years ago
R&D

Am­gen qui­et­ly kills an obe­si­ty pro­gram, cast­ing bleak fu­ture for once-promis­ing tar­get

4 years ago
R&D
Discovery

Open sea­son on PBMs but FTC votes against dig­ging in­to their an­ti-com­pet­i­tive prac­tices fur­ther

4 years ago
R&D

GSK gets tem­po­rary re­strain­ing or­der against for­mer em­ploy­ee ac­cused of steal­ing trade se­crets

4 years ago
Pharma

Is the clock tick­ing on Mod­er­na's patent promise? Ac­tivists fear South African patents could hin­der vac­cine ...

4 years ago
Pharma
Coronavirus
First page Previous page 579580581582583584585 Next page Last page
A service from the Financial Times